Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Bente, Frimodt-Moller"'
Autor:
Kazuto Nishio, MD, PhD, Takashi Seto, MD, Makoto Nishio, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, MS, Kazuko Sakai, PhD, Koichi Goto, MD, PhD, Terufumi Kato, MD, Yoichi Nakanishi, MD, PhD, Toshiaki Takahashi, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Katsuyuki Kiura, MD, PhD, Yuichiro Ohe, MD, PhD, Tomohide Tamura, MD, Carla Visseren-Grul, MD, Bente Frimodt-Moller, MSc, Rebecca R. Hozak, PhD, Sameera R. Wijayawardana, PhD, Annamaria Zimmermann, MS, Gosuke Homma, PhD, Sotaro Enatsu, MD, PhD, Kazuhiko Nakagawa, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 6, Pp 100171- (2021)
Introduction: The phase 3 RELAY global study (NCT02411448) revealed significant improvement in progression-free survival (PFS) with ramucirumab plus erlotinib (RAM + ERL) compared with placebo plus ERL (PL + ERL) in untreated EGFR-mutated metastatic
Externí odkaz:
https://doaj.org/article/3e75f1f8e2034c7bb7923044f4c4d8a7
Autor:
John V. Heymach, Terafumi Kato, Edward B. Garon, Carla Visseren-Grul, Kazuhiko Nakagawa, Jonathan H. Goldman, Monique B. Nilsson, Martin Reck, Bente Frimodt-Moller, L. Arés, Xiuning Le, Katharina Wolff
Publikováno v:
Journal of Thoracic Oncology. 16:205-215
The VEGF pathway has been recognized as a key mediator of angiogenesis to support tumorigenesis. Multiple therapeutic agents targeting VEGF and VEGF receptors have been developed and approved for use in NSCLCs. Preclinical studies have found that the
Autor:
Annamaria Zimmermann, Gosuke Homma, Relay investigators, Kazuhiko Nakagawa, Bente Frimodt-Moller, Makoto Nishio, Carla Visseren-Grul, Sotaro Enatsu, Jin-Yuan Shih, Edward B. Garon, Chao-Hua Chiu, Takashi Seto, Martin Reck, Keunchil Park, Kiyotaka Yoh, Fumio Imamura
Publikováno v:
Cancer Science
In the global phase III RELAY study, ramucirumab plus erlotinib (RAM + ERL) demonstrated superior progression‐free survival (PFS) to placebo plus erlotinib (PL + ERL) in untreated patients with epidermal growth factor receptor (EGFR) mutation‐pos
Autor:
Ernest Nadal, Hidehito Horinouchi, Jin-Yuan Shih, Kazuhiko Nakagawa, Martin Reck, Edward B. Garon, Yu-Feng Wei, Jens Kollmeier, Bente Frimodt-Moller, Emily Barrett, Olga Lipkovich, Carla Visseren-Grul, Silvia Novello
Publikováno v:
Drug Safety
Introduction RELAY was a global, double-blind, placebo-controlled phase III study that demonstrated superior progression-free survival (PFS) for ramucirumab plus erlotinib (RAM + ERL) versus placebo plus erlotinib (PBO + ERL) in the first-line treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f054eb1ede4d12b4770ad3ee81bcc29
http://hdl.handle.net/2318/1849590
http://hdl.handle.net/2318/1849590
Autor:
Carla Visseren-Grul, Santiago Ponce Aix, Shinji Atagi, Annamaria Zimmermann, Edward B. Garon, Kiyotaka Yoh, Katherine B. Winfree, Bente Frimodt-Moller, Relay investigators, Kazuhiko Nakagawa, Denis Moro-Sibilot, Martin Reck
Publikováno v:
Current Medical Research and Opinion. 36:1667-1675
In the phase 3 RELAY trial, ramucirumab/erlotinib demonstrated superior progression-free survival (PFS) over placebo/erlotinib in patients with EGFR-mutated metastatic NSCLC (median PFS 19.4 versus...
Autor:
Kazuhiko Nakagawa, Edward B Garon, Takashi Seto, Makoto Nishio, Santiago Ponce Aix, Luis Paz-Ares, Chao-Hua Chiu, Keunchil Park, Silvia Novello, Ernest Nadal, Fumio Imamura, Kiyotaka Yoh, Jin-Yuan Shih, Kwok Hung Au, Denis Moro-Sibilot, Sotaro Enatsu, Annamaria Zimmermann, Bente Frimodt-Moller, Carla Visseren-Grul, Martin Reck, Quincy Chu, Alexis Cortot, Jean-Louis Pujol, Elizabeth Fabre, Corinne Lamour, Helge Bischoff, Jens Kollmeier, Martin Kimmich, Walburga Engel-Riedel, Stefan Hammerschmidt, Wolfgang Schütte, Konstantinos Syrigos, James Chung Man Ho, Kwok-Hung Au, Andrea Ardizzoni, Giulia Pasello, Vanessa Gregorc, Alessandro Del Conte, Domenico Galetta, Toshiaki Takahashi, Toru Kumagai, Katsuyuki Hotta, Yasushi Goto, Yukio Hosomi, Hiroshi Sakai, Yuichi Takiguchi, Young Hak Kim, Takayasu Kurata, Hiroyuki Yamaguchi, Haruko Daga, Isamu Okamoto, Miyako Satouchi, Satoshi Ikeda, Kazuo Kasahara, Shinji Atagi, Koichi Azuma, Keisuke Aoe, Yoshitsugu Horio, Nobuyuki Yamamoto, Hiroshi Tanaka, Satoshi Watanabe, Naoyuki Nogami, Tomohiro Ozaki, Ryo Koyama, Tomonori Hirashima, Hiroyasu Kaneda, Keisuke Tomii, Yuka Fujita, Masahiro Seike, Naoki Nishimura, Terufumi Kato, Masao Ichiki, Hideo Saka, Katsuya Hirano, Yasuharu Nakahara, Shunichi Sugawara, Sang-We Kim, Young Joo Min, Hyun Woo Lee, Jin-Hyoung Kang, Ho Jung An, Ki Hyeong Lee, Jin-Soo Kim, Gyeong-Won Lee, Sung Yong Lee, Aurelia Alexandru, Anghel Adrian Udrea, Óscar Juan-Vidal, Ernest Nadal-Alforja, Ignacio Gil-Bazo, Santiago Ponce-Aix, Belén Rubio-Viqueira, Miriam Alonso Garcia, Enriqueta Felip Font, Jose Fuentes Pradera, Juan Coves Sarto, Meng-Chih Lin, Wu-Chou Su, Te-Chun Hsia, Gee-Chen Chang, Yu-Feng Wei, Jian Su, Irfan Cicin, Tuncay Goksel, Hakan Harputluoglu, Ozgur Ozyilkan, Ivo Henning, Sanjay Popat, Olivia Hatcher, Kathryn Mileham, Jared Acoba, Edward Garon, Gabriel Jung, Moses Raj, William Martin, Shaker Dakhil
Publikováno v:
The Lancet Oncology. 20:1655-1669
Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the approach is not widely implemented. RELAY assessed erlotinib, an EGFR tyrosine kinase inh
Autor:
Carla Visseren-Grul, Relay investigators, Kazuhiko Nakagawa, Bente Frimodt-Moller, S. Ponce Aix, E. Nadal, E. Fabre, Martin Reck, Denis Moro-Sibilot, Silvia Novello, M. Alonso Garcia, Edward B. Garon, Annamaria Zimmermann
Publikováno v:
Cancer Treatment and Research Communications, Vol 27, Iss, Pp 100378-(2021)
Background: In EGFR mutation-positive NSCLC, dual EGFR/VEGFR inhibition compared to EGFR alone increases anti-tumor efficacy. The Phase III RELAY trial demonstrated superior PFS for ramucirumab plus erlotinib (RAM + ERL) over placebo plus erlotinib (
Autor:
Kazuto, Nishio, Takashi, Seto, Makoto, Nishio, Martin, Reck, Edward B, Garon, Kazuko, Sakai, Koichi, Goto, Terufumi, Kato, Yoichi, Nakanishi, Toshiaki, Takahashi, Nobuyuki, Yamamoto, Katsuyuki, Kiura, Yuichiro, Ohe, Tomohide, Tamura, Carla, Visseren-Grul, Bente, Frimodt-Moller, Rebecca R, Hozak, Sameera R, Wijayawardana, Annamaria, Zimmermann, Gosuke, Homma, Sotaro, Enatsu, Kazuhiko, Nakagawa
Publikováno v:
JTO Clinical and Research Reports
Introduction The phase 3 RELAY global study (NCT02411448) revealed significant improvement in progression-free survival (PFS) with ramucirumab plus erlotinib (RAM + ERL) compared with placebo plus ERL (PL + ERL) in untreated EGFR-mutated metastatic N
Autor:
Kiyotaka, Yoh, Shinji, Atagi, Martin, Reck, Edward B, Garon, Santiago, Ponce Aix, Denis, Moro-Sibilot, Katherine B, Winfree, Bente, Frimodt-Moller, Annamaria, Zimmermann, Carla, Visseren-Grul, Kazuhiko, Nakagawa
Publikováno v:
Current medical research and opinion. 36(10)
In the phase 3 RELAY trial, ramucirumab/erlotinib demonstrated superior progression-free survival (PFS) over placebo/erlotinib in patients withPatients received oral erlotinib (150 mg daily) plus intravenous ramucirumab (10 mg/kg) or placebo Q2W unti
Autor:
Benjamin Besse, Ingel K. Demedts, Bente Frimodt-Moller, Gilles Robinet, Fabrice Barlesi, J. Vansteenkiste, Anas Gazzah, Victoria Soldatenkova, Jose Fuentes Pradera, Jong Seok Kim
Publikováno v:
Lung Cancer
Lung Cancer, 2019, 137, pp.136-143. ⟨10.1016/j.lungcan.2019.09.002⟩
Lung Cancer, Elsevier, 2019, 137, pp.136-143. ⟨10.1016/j.lungcan.2019.09.002⟩
Digital.CSIC. Repositorio Institucional del CSIC
instname
Lung Cancer, 2019, 137, pp.136-143. ⟨10.1016/j.lungcan.2019.09.002⟩
Lung Cancer, Elsevier, 2019, 137, pp.136-143. ⟨10.1016/j.lungcan.2019.09.002⟩
Digital.CSIC. Repositorio Institucional del CSIC
instname
[Objectives] Necitumumab, an anti-EGFR antibody, and abemaciclib, a CDK4/6 inhibitor, have shown activity in patients with non-small cell lung cancer (NSCLC) and have non-overlapping toxicities. A 2-part, single-arm, multicenter, phase 1b trial was c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3c8df3f3a9f6dc31d7993e9aa5c3179
https://hal.science/hal-02505039
https://hal.science/hal-02505039